CAMBRIDGE, England & STEVENAGE, England--(BUSINESS WIRE)--Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), and ...
Researchers have completed the first phase of a collaboration integrating robotic cell processing with automated manufacturing platforms, reducing manual steps while maintaining biological integrity.
Cellular Origins reports that the company completed the first phase of its collaboration with Fresenius Kabi designed to help scale the manufacturing of cell and gene therapies using advanced robotics ...
The market is projected to surpass $16 billion by 2033, reflecting its rapid transition from research labs into clinical applications such as oncology and prenatal testing. Yet despite this momentum, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results